Clinical Trials
31 trialsDOT-H
Fundação Bahiana de Infectologia
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
National Institutes of Health Clinical Center (CC)
Tissue Collection for Studies of Lymph Cancer
National Institutes of Health Clinical Center (CC)
A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
Bristol-Myers Squibb
DS-3201b in Participants With Lymphomas
Daiichi Sankyo
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma
University of Miami
A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma
SymBio Pharmaceuticals
Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies
Chongqing Precision Biotech Co., Ltd
Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab
Kyowa Kirin Co., Ltd.
KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
Kyowa Kirin Co., Ltd.
Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia
National Institutes of Health Clinical Center (CC)
Ruxolitinib for Adult T-Cell Leukemia
National Institutes of Health Clinical Center (CC)
Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)
National Institutes of Health Clinical Center (CC)
Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL
miRagen Therapeutics, Inc.
Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia
National Institutes of Health Clinical Center (CC)
A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma
Celgene
MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study
MP Biomedicals, LLC
A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma
Celgene
Dual Algorithm Post Market Clinical Study
MP Biomedicals, LLC
Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15
Kyowa Kirin Co., Ltd.
Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma
Kyowa Kirin Co., Ltd.
ATLL
Washington University School of Medicine
A Study for Aggressive Adult T-cell Leukemia-lymphoma (ATLL)
Japan Clinical Oncology Group
Lenalidomide in HTLV-1 Adult T-Cell Leukemia
Columbia University
Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma
Novartis
Campath-1H for Treating Adult T-Cell Leukemia/Lymphoma
National Institutes of Health Clinical Center (CC)
Phase I Study of KW-0761 in Relapsed Patients With CCR4-Positive ATL and PTCL
Kyowa Kirin Co., Ltd.
Anti-Tac for Treatment of Leukemia
National Institutes of Health Clinical Center (CC)
Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas
University of Alabama at Birmingham
Evaluation of the MP Diagnostics HTLV Blot 2.4
MP Biomedicals, LLC